NRX Pharmaceuticals, Inc.

Big Rock Partners Acquisition Corp. (Nasdaq: BRPA), sponsored by Big Rock Partners, completed its initial public offering in 2018 as a blank-check company targeting the healthcare and biopharmaceutical sector. The vehicle filed a Form 10-Q with the SEC on August 8, 2018, reflecting its status as an active search-stage SPAC during that period. BRPA subsequently entered into a business combination with NRX Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders and acute respiratory conditions, transitioning the entity from a shell company into an operating pharmaceutical firm. To access full filing histories, deal timelines, and SPAC analytics for BRPA and hundreds of other transactions, sign up for SpacDesk.